{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination broadens the range of tumor antigens presented to the immune system.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
                    "line_ref": "L28"
                },
                {
                    "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
                    "line_ref": "L29"
                }
            ],
            "caveat": "The reported broadening of the immunopeptidome is based on mouse models and may not fully translate to human tumors."
        },
        {
            "claim_id": "C02",
            "claim": "mRNA vaccination in tumors boosts type I interferon signaling, a key pathway for anti-tumor immunity.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
                    "line_ref": "L31"
                },
                {
                    "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
                    "line_ref": "L39"
                }
            ],
            "caveat": "The observed interferon response is primarily in mouse models; the human response may differ in magnitude and character."
        },
        {
            "claim_id": "C03",
            "claim": "The combination of intratumoral mRNA vaccine and anti-PD-L1 therapy increases the infiltration of CD8+ T-cells into the tumor.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
                    "line_ref": "L33"
                },
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                }
            ],
            "caveat": "The increase in T-cell density is reported as a fold-change in mouse models and may not directly correlate with clinical efficacy in humans."
        },
        {
            "claim_id": "C04",
            "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic patients receiving ICI treatment.",
            "strength": "tentative",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A",
                    "line_ref": "L30"
                },
                {
                    "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
                    "line_ref": "L49"
                }
            ],
            "caveat": "This is a retrospective, non-randomized analysis, so a causal link cannot be firmly established. Confounding factors could be responsible for the observed association."
        }
    ]
}